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Abstract: Serpinb1 is an inhibitor of neutrophil granule ser-
ine proteases cathepsin G, proteinase-3 and elastase. One 
of its core physiological functions is to protect neutrophils 
from granule protease-mediated cell death. Mice lacking 
Serpinb1a (Sb1a-/-), its mouse ortholog, have reduced bone 
marrow neutrophil numbers due to cell death mediated 
by cathepsin G and the mice show increased susceptibility 
to lung infections. Here, we show that conditional  deletion 
of Serpinb1a using the Lyz2-cre and Cebpa-cre knock-in 
mice effectively leads to recombination-mediated deletion 
in neutrophils but protein-null neutrophils were only 
obtained using the latter recombinase-expressing strain. 
Absence of Serpinb1a protein in neutrophils caused neu-
tropenia and increased granule permeabilization-induced 
cell death. We then generated transgenic mice express-
ing human Serpinb1 in neutrophils under the human 
MRP8 (S100A8) promoter. Serpinb1a expression levels in 
founder lines correlated positively with increased neu-
trophil survival when crossed with Sb1a-/- mice, which 
had their defective neutrophil phenotype rescued in the 
higher expressing transgenic line. Using new conditional 
and transgenic mouse models, our study demonstrates 
the presence of a relatively low Serpinb1a protein thresh-
old in neutrophils that is required for sustained survival. 
These models will also be helpful in delineating recently 
described functions of Serpinb1 in metabolism and cancer.
Keywords: cell death; cre; serine protease; serpin.
Introduction
Neutrophils (PMNs) are granulocytes with central func-
tions in inflammatory disease and in innate immunity 
against microbes (Kruger et  al., 2015). Because isolated 
PMNs are short-lived, they are poorly amenable to in vitro 
manipulation such as RNA interference and transfection. 
The use of genetic engineering in mice has thus been 
helpful in delineating molecular pathways in PMN home-
ostasis and functions. With this approach, we and others 
have shown that PMN survival in vivo depends in part 
on inhibition of granule serine proteases by Serpinb1a 
(Benarafa et al., 2011; Baumann et al., 2013; Loison et al., 
2014). Human SERPINB1 and its mouse homolog Serpinb1a 
are intracellular inhibitors of neutrophil serine proteases 
cathepsin G, proteinase-3 and elastase (Cooley et al., 2001; 
Benarafa et  al., 2002). Serpinb1a-deficient mice (Sb1a-/-) 
present a profound reduction in PMN survival, leading 
to a neutropenia in the bone marrow (BM) in steady 
state conditions as well as in the periphery during infec-
tion (Benarafa et al., 2007, 2011). Serpinb1a is expressed 
broadly in all leukocytes including hematopoietic stem 
cells (HSCs) but also at high levels in many organs such 
as lungs, liver, pancreas and prostate (Benarafa et  al., 
2002). There is an emerging literature correlating varia-
tions of Serpinb1 expression with progression of various 
types of cancers and inflammatory diseases (Ashida et al., 
2004; Popova et al., 2006; Yasumatsu et al., 2006; Tseng 
et al., 2009; Naito et al., 2010; Cui et al., 2014; Zhao et al., 
2014; Huasong et al., 2015; Sheng et al., 2015; El Ouaamari 
et  al., 2016). Therefore, additional models to investigate 
specific functions of this serpin in vivo are needed. Here, 
we developed and validated tools to conditionally delete 
Serpinb1a using cre-loxP technology in myeloid cells and, 
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inversely, we generated a transgenic mouse expressing 
human Serpinb1 (hSerpinb1) in PMNs that rescues the BM 
neutropenia of Sb1a-/- mice.
Results
Lyz2-driven cre recombination of Serpinb1a 
floxed allele in neutrophils
We have previously targeted Serpinb1a in embryonic stem 
(ES) cells using a 3-loxP strategy (Benarafa, 2011). Tran-
sient transfection of an ES cell clone with a cre express-
ing plasmid allowed removal of the selection cassette and 
the generation of ES cell clones with a constitutive deleted 
allele as well as clones with a conditional allele (Figure 1). 
The characterization of constitutive Sb1a-/- mice derived 
from ES cells carrying a deleted allele was described previ-
ously (Benarafa et al., 2007, 2011). To investigate the phe-
notype of mice lacking Serpinb1a principally in myeloid 
cells, conditional Sb1aF/F mice were interbred with the 
commonly used knock-in mice expressing the cre recom-
binase from the endogenous Lyz2 (also known as LysM) 
promoter (Lyz2cre/cre)(Clausen et al., 1999). PCR analysis of 
genomic DNA of sorted BM leukocyte subsets confirmed 
almost complete cre-mediated recombination of the Ser-
pinb1a locus in PMNs, partial recombination in myelocytes 
and, as expected, no recombination in B cells (Figure 2A). 
However, absolute numbers and percentage of PMNs in 
the BM of Lyz2cre/creSb1aF/- mice were normal and equivalent 
to those of Sb1a+/+, Sb1a+/- and Lyz2+/+Sb1aF/- mice (Figure 
2B), whereas Sb1a-/- mice had reduced PMN numbers as we 
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Figure 1: Generation of Serpinb1aF/F mice.
Shown at the top is the targeted Serpinb1a locus with 3-loxP sites 
(black triangles) in ES cells. Cre recombinase in ES cells (indicated 
by white arrows) generated two new alleles: either a floxed  
(Serpinb1atm1.2(flox)Cben) allele or a deleted (Serpinb1atm1.1Cben) allele. 
In vivo recombination (red arrow) of a floxed allele in Serpinb1aF/F 
(Sb1aF/F) mice is expected to generate a deleted allele in cell line-
ages expressing cre. Deletion of exon 7, which encodes the reactive 
center loop of the serpin, was previously shown to be an effective 
null allele (Benarafa et al., 2007).
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Figure 2: Lyz2cre/cre deletion of Serpinb1aF/F.
(A) PCR analysis of genomic DNA isolated from flow cytometry sorted 
BM cells isolated from Lyz2cre/creSerpinb1aF/F mice. Arrows indicate 
expected size of PCR products for Sb1a alleles (deleted 500bp; 
floxed 410bp; WT 250bp) as indicated by ear biopsy standard 
samples. Total number and percentage of BM PMN (B) and B cells 
(C). BM and blood cell numbers and percentages were analyzed by 
Mann-Whitney U-test (****p < 0.001). (D) Western blot analysis of 
Serpinb1a and β-actin of flow-sorted BM PMNs.
previously reported (Benarafa et al., 2011; Baumann et al., 
2013). As expected, B cell numbers were not significantly 
different between all genotypes (Figure 2C). Western blot 
analysis of sorted BM cells revealed that Serpinb1a protein 
was still detectable in PMN lysates of Lyz2cre/creSb1aF/F mice 
at levels comparable to those of Sb1a+/- mice (Figure 2D). 
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These findings demonstrate that Lyz2cre-driven deletion of 
the Serpinb1a locus does not produce PMNs defective in 
Serpinb1a protein despite efficient DNA recombination in 
PMNs.
Cebpa-driven cre recombination of Serpinb1a 
floxed allele in neutrophils
To evaluate an alternative model, Sb1aF/F mice were inter-
crossed with mice expressing the cre recombinase from 
endogenous CCAAT/enhancer binding protein α (C/EBPα) 
promoter, which drives expression at an earlier develop-
mental stage in myelopoiesis than Lyz2 (Wölfler et  al., 
2010). Efficient deletion of the floxed allele was observed 
in PMNs, myelocytes and monocytes but not in B cells 
(Figure 3A). Western blot analysis also confirmed absence 
of Serpinb1a protein in sorted PMN lysates of Cebpa+/cre-
Sb1aF/- mice (Figure 3B). Accordingly, myeloid cell-specific 
deletion of Serpinb1a in Cebpa+/creSb1aF/- mice reproduced 
the phenotype of Sb1a-/- mice characterized by reduced 
absolute numbers and significantly lower percentage 
of PMNs in the BM (Figure 4A). As in Sb1a-/- mice, other 
cell subsets in the BM were not altered in Cebpa+/creSb1aF/- 
mice (Figure 3B; Supplementary Figure S1A,B). Numbers 
of PMNs and other leukocyte subsets in blood as well as 
other blood parameters were not altered (Figure 4C; Sup-
plementary Figure S1C; Table 1), which is consistent with 
the phenotype of Sb1a-/- mice.
PMNs are highly susceptible to granule permeabili-
zation-induced cell death caused by L-leucyl-L- leucine 
methyl ester (LLME). LLME treatment of PMNs of Cebpa+/cre 
Sb1aF/- mice showed reduced survival similar to those 
of control Cebpa+/creSb1a-/- littermates and of Sb1a-/- 
mice (Figure 4D). As shown previously for Sb1a-/- PMNs 
(Baumann et al., 2013), caspase inhibition with Q-VD-OPh 
had no protective effect on cell death of Cebpa+/creSb1aF/- 
PMNs. Taken together, these data demonstrate that mye-
loid-specific deletion of Serpinb1a largely replicates the 
PMN phenotype of constitutive Sb1a-/- mice.
Transgenic rescue of Sb1a-/- neutrophils with 
human SERPINB1
Human SERPINB1 cDNA was cloned downstream of the 
human S100A8 (MRP8) promoter and was injected in the 
pronucleus of C57BL/6J oocytes. Founder transgenic mice 
were identified by PCR analysis (Figure 5A). Three of the 
male founders were crossed with Sb1a-/- mice. Western blot 
analysis of PMN lysates revealed that the progeny of founder 
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Figure 3: Cebpa+/cre deletion of Serpinb1a.
(A) Genotyping PCR analysis of genomic DNA isolated from flow 
cytometry sorted BM cells of Cebpa+/creSb1aF/- mice. Arrows indicate 
expected size of PCR products for Serpinb1a alleles (deleted 500 
bp; floxed 410 bp; WT 250 bp) as indicated by ear biopsy stand-
ard samples. (B) Western blot analysis for Serpinb1a and β-actin 
of flow-sorted BM PMNs. Serpinb1a-protease complex and partly 
degraded complex are indicated by an arrowhead and an asterisk, 
respectively.
3 (Tg3) typically expressed more Serpinb1 protein than 
the progeny of Tg2 and that Serpinb1 expression was not 
detectable in the progeny of Tg4 (Figure 5B). Percentage of 
PMNs in the BM of the different Tg lines correlated with the 
expression levels of each line (Figure 5C).  Correspondingly, 
protection from LLME-induced granule permeabiliza-
tion and cell death correlated with Serpinb1 expression 
levels in the different Tg lines. Specifically, survival of high 
expressors Tg3 PMNs was rescued to levels of WT PMNs. 
Reduced survival was observed in PMNs of the Tg2 and 
Tg4 lines and lowest survival was expectedly observed for 
Sb1a-/- PMNs (Figure 5D). Therefore, these data demonstrate 
that Serpinb1 functions as a rheostat in protecting PMNs 
from granule protease-mediated death in vivo and in vitro.
Discussion
We report that PMNs lacking Serpinb1a protein were 
successfully generated in mice expressing the cre 
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models. Failure to generate Serpinb1a protein-null PMNs 
despite efficient genomic recombination in Lyz2cre/creSb1aF/- 
mice is likely due to a combination of factors. First, the 
floxed Serpinb1a locus was not fully recombined during 
early stages of granulopoiesis. Second, low levels of Ser-
pinb1a protein may suffice to support PMN survival. Since 
Serpinb1a transcription is active in HSCs and peaks early 
in granulopoiesis at the promyelocyte/myelocytes stages 
(Benarafa et al., 2011), Serpinb1a protein is already accu-
mulating in the cell before the floxed gene is recombined. 
Thus, sufficient Serpinb1a protein levels may be sustained 
throughout PMNs’ short life-span and maintain normal 
PMN levels in the BM of Lyz2cre/creSb1aF/- mice.
PMNs develop in the BM from hematopoietic stem 
cells via bipotent granulocyte/macrophage progeni-
tors (GMPs), which can develop into monocyte or PMN 
 lineages. Cebpa is expressed at high levels at the GMP 
stage, whereas Lyz2 expression peaks later and indepen-
dently in both granulocyte and monocyte lineages. Cre-
mediated recombination using these two cre knock-in 
models has been widely and successfully used to delete 
genes in the myeloid compartment. Yet, as we have seen, 
the timing of cre expression as well as the lineage may be 
important in achieving effective gene recombination in 
early stages of granulopoiesis. Recombination efficiency 
at different stages of hematopoiesis also differs depend-
ing on the targeted locus and therefore making the right 
choice of a cre deleter strain can be difficult and will 
always require experimental confirmation. Our study 
highlights that it remains crucial that gene deletion and 
protein levels are effectively measured particularly when 
recombination appears to have no effect on the studied 
phenotype as shown by the absence of BM neutropenia 
in Lyz2cre/creSb1aF/- mice. Far from a theoretical question, in 
studies where protein levels were not verified and showing 
no phenotype in mice with deleted myeloid cells (Rupec 
et al., 2005; Kirkland et al., 2012), incomplete protein dele-
tion may have led to overlooking the contribution of the 
studied proteins in myeloid cells.
We showed here that the extent of the rescue of PMN 
survival by transgenic expression of human SERPINB1 in 
Sb1a-/- mice was dependent on transgene expression levels. 
Evaluating the threshold levels of Serpinb1 necessary for 
cytoprotection is challenging because Serpinb1-protease 
complexes are processed rapidly into post-complex cleav-
age forms when proteases are in excess (Cooley et al., 2011). 
Furthermore, the antibody used in Western blot analysis 
may react differently with endogenous mouse and trans-
genic human Serpinb1 as well as with the different com-
plexes. In the Sb1a-/-Tg2 progeny, the hSerpinb1 transgene 
is relatively weakly expressed and only detectable in 
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Figure 4: Deletion of Serpinb1a in myeloid cells is sufficient to 
reduce PMN survival.
Total number and percentage of BM PMNs (A), BM monocytes (B). 
Percentage of blood PMNs and monocytes (C). BM cell numbers and 
percentages were analyzed by Mann-Whitney U-test (**p < 0.01). 
(D) Survival of PMNs treated with LLME (100 μM) in the presence 
or absence of the caspase inhibitor Q-VD-OPh (50 μM). Viability 
was assessed using Annexin V-FITC and 7- AAD staining of Ly-6G+ 
cells and analyzed by Student’s t-test relative to wild-type PMNs 
(*p < 0.05; **p < 0.01; ***p < 0.001).
recombinase driven by the Cebpa promoter but not by 
the Lyz2 promoter. Accordingly, PMNs of Cebpa+/creSb1aF/- 
mice, but not PMNs of Lyz2cre/creSb1aF/- mice, recapitulated 
the phenotype of Sb1a-/- PMNs with reduced survival 
in vitro and in vivo. We found that the floxed Serpinb1a 
gene was essentially recombined in mature PMNs in both 
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Table 1: Hematological analysis of whole blood.
Genotype WBC ( × 106 cells/ml) RBC ( × 109 cells/ml) PLT ( × 106 cells/ml) Hemoglobin (g/dl) Hematocrit (%) n
Sb1a+/+ 6.84±3.4 9.57±0.4 1295±248 15.8±0.7 52.7±2.6 8
Sb1a+/- 6.41±1.6 9.38±0.7 1309±160 15.6±1.2 48.2±5.4 7
Sb1a-/- 6.13±2.9 9.57±0.6 1656±129 16.3±0.4 51.2±3.0 4
Sb1aF/- 6.06±2.6 9.66±0.7 1479±182 16.2±1.0 50.4±4.3 13
Cepba+/creSb1a+/- 6.47±2.4 9.55±0.7 1361±258 15.9±1.2 49.9±5.1 8
Cepba+/creSb1a-/- 5.46±0.8 9.49±0.7 1532±187 15.7±1.0 50.3±2.9 5
Cepba+/creSb1aF/- 5.69±1.2 9.80±0.6 1348±142 16.1±0.9 51.0±4.4 9
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Figure 5: Rescue of Serpinb1a-/- PMN survival by transgenic expression of human SERPINB1.
(A) PCR analysis of genomic DNA of transgenic founders using a single primer pair that recognizes both the human SERPINB1 transgene 
cDNA (266 bp) and mouse Serpinb1a gene (460 bp, which includes an intronic sequence). (B) Western blot analysis for SERPINB1 and β-actin 
of flow-sorted BM PMNs from offsprings of Tg founders 2, 3 and 4. hSerpinb1-protease complex and partly degraded complex are indicated 
by an arrowhead and an asterisk, respectively. (C) Percentage of PMN numbers in the BM of Sb1a-/-Tg2, Sb1a-/-Tg3 and Sb1a-/-Tg4 mice 
(**p < 0.01). (D) Survival of PMNs treated with LLME (100 μM) in the presence or absence of the caspase inhibitor Q-VD-OPh (50 μm). Viability 
was assessed using Annexin V-FITC and 7- AAD staining of Ly-6G+ cells and analyzed by Student’s t-test relative to Sb1a-/- PMNs (*p < 0.05; 
***p < 0.001).
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complex with proteases. With all the caveats in mind for 
such a comparison, it suggests that the Tg2 line expresses 
substantially lower levels than heterozygous Sb1a+/- mice, 
where active mouse Serpinb1a can be detected. Yet, in the 
Sb1a-/-Tg2 mice, we observed a partial rescue of the survival 
phenotype in vivo and of LLME-induced death in vitro. 
In the Sb1a-/-Tg4 progeny, the transgene was not detect-
able by Western blot analysis, suggesting very low or no 
expression and, accordingly, PMN numbers in the BM were 
as low as in Sb1a-/- mice. In the higher expressing trans-
genic line (Tg3), hSERPINB1 transgene was found in active 
and complex forms and PMN survival was fully rescued 
in vitro and in vivo. This new transgenic model will allow 
us to evaluate the function of the ubiquitously expressed 
 Serpinb1a in non-hematopoietic tissues in the absence of 
the PMN survival defect in various disease models.
More targeted deletions in tissue or cell subsets 
could then follow using Sb1aF/- mice crossed with other 
cre-expressing mouse lines. Of note, reporter analysis of 
Cebpa+/cre mice showed recombination in the liver and 
lung airway epithelium (Wölfler et  al., 2010). It is thus 
likely that the Sb1aF/- locus was recombined in some non-
hematopoietic cells of Cebpa+/creSb1aF/- mice. We previously 
demonstrated that, in BM chimera, deletion of Sb1a in the 
hematopoietic compartment was necessary and sufficient 
to reproduce the phenotype of Sb1a-/- mice (Baumann 
et al., 2013). Therefore, effective deletion of Serpinb1a in 
myeloid cells is undoubtedly the cause of BM neutrope-
nia in Cebpa+/creSb1aF/- mice. However, careful scrutiny of 
Sb1a expression in various cell types and time points will 
be required when using Cebpa+/creSb1aF/- mice in systemic 
disease models. Finally, HSCs of Cebpa+/creSb1aF/- mice may 
be most useful to reconstitute the immune system of irra-
diated mice to generate myeloid-specific deficiency.
Transgenic mice expressing cre under the hMRP-8 
promoter (S100A8) and knock-in models such as neu-
trophil elastase knock-in mice (Elanetm1(cre)Roes) or Ly6G 
knock-in (Catchup) mice (Ly6gtm2621(Cre-tdTomato)Arte) are addi-
tional models for PMN-specific gene deletion in PMNs 
(Tkalcevic et al., 2000; Passegué et al., 2004; Hasenberg 
et al., 2015). These models have reduced targeting of the 
monocytic lineage than Lyz2 and Cebpa cre knock-in mice 
used here. Whether Serpinb1a protein-null PMNs can be 
obtained using these models remains to be tested but 
is unlikely given the persistence of the protein in PMNs 
of Lyz2cre/creSb1F/- mice and the small amount of protein 
rescue needed for mitigating the Sb1a-/- phenotype in 
transgenic mice. For example, deletion of the Fcgr4 gene 
was complete and specific for PMNs at the genomic level 
in Catchup mice. While the mice showed a specific pheno-
type due to gene deletion, FcRIV expression on the PMN 
surface measured by flow cytometry was only reduced by 
50% (Hasenberg et  al., 2015). Experimental approaches 
using cre-mediated recombination in PMNs thus remain 
challenging in choosing the right cre-expressing model(s) 
and in the interpretation of the data. In addition to time 
and resources to generate the mice, it requires specific 
attention to the target gene expression pattern, protein 
stability and functional protein threshold to choose the 
right cre-expressing model(s) and to draw appropriate 
conclusions.
In summary, we showed that the survival of PMNs 
depends on a threshold level of Serpinb1 below which 
serine protease activity is not controlled, leading to cell 
death. These findings are consistent with the mode of 
action of Serpinb1 as a stoichiometric inhibitor of neutro-
phil proteases. Our study further supports the notion that 
intracellular serpins such as clade B serpins in vertebrates 
and serpins of Caenorhabditis elegans have a fundamen-
tal cytoprotective function (Bird, 1999; Zhang et al., 2006; 
Luke et  al., 2007; Tan et  al., 2013; Bird et  al., 2014). We 
have previously demonstrated that BM neutropenia of 
Sb1a-/- mice is dependent on cathepsin G in vivo (Baumann 
et  al., 2013). In addition, Serpinb1 prevents spontane-
ous PMN apoptosis by inhibiting proteinase-3-mediated 
cleavage and activation of caspase-3 (Loison et al., 2014). 
PMNs are exquisitely sensitive to death after granule 
leakage induced by LLME treatment and cathepsin G is 
required for this caspase-independent cell death pathway 
that is critically regulated by Serpinb1 (Baumann et  al., 
2013). Similarly, Serpinb9 protects cytotoxic lymphocytes 
against granzyme B-mediated death following granule 
leakage induced by LLME treatment or by T cell activa-
tion (Bird et al., 2014). Serpinb6a is another intracellular 
serpin inhibitor of cathepsin G that is expressed in PMNs 
and may contribute to the protease shield against granule 
permeability-induced cell death. Ongoing studies using 
multiple targeting of the large locus of clade B serpin 
locus on mouse chromosome 13 will determine the rela-
tive contributions of Serpinb1a, Serpinb6a, Serpinb9 and 
additional understudied serpin paralogs in cellular home-
ostasis. The models described here will provide important 
tools for these studies.
Materials and methods
Ethics statement
All animal studies were approved by the Cantonal Veterinary Office 
of the canton of Bern and conducted in accordance with the Swiss 
federal legislation on animal welfare.
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Mouse models for conditional deletion of Serpinb1a
Serpinb1a-/- (Serpinb1atm1.1Cben) mice were generated in 129S6/SvEvTac 
(129S6) background (Benarafa et  al., 2007) and backcrossed in 
C57BL/6J background (Benarafa et  al., 2011). The latter were used 
in this study. Serpinb1aF/F (Serpinb1atm1.2(flox)Cben) were generated in 
parallel with Sb1a-/- mice. Briefly, 129S6/W4 ES cells (Taconic) were 
targeted by homologous recombination with a linearized plasmid 
described previously (Benarafa, 2011). Homologous recombinant 
clones with 3-loxP sites were transiently transfected with Cre recom-
binase to excise the floxed CMV-HYG/TK positive/negative selection 
cassette. Cells were further selected with gancyclovir to eliminate 
the clones where the deletion of the selection cassette did not occur. 
While most clones tested had recombined the first and third loxP sites 
to generate the deleted allele (serpinB1atm1.1Cben), we also found clones 
that recombined the second and third loxP sites, leaving an allele 
(serpinB1atm1.2(flox)Cben) with a floxed exon 7 (Figure 1). ES cells (clone 
2F7-F5) were injected into blastocysts at the transgenic core facility 
of the Brigham and Women Hospital (Boston). Sb1a+/F heterozygous 
mice were generated from chimeric mice. During backcrossing into 
C57BL/6J for 10 generations, Sb1a+/F breeders were also selected 
based on the polymorphic PCR markers D13Mit117 and D13Mit16 to 
reduce the portion of chromosome 13 belonging to the 129S6 strain 
to  < 3–4  cM on each side of the Serpinb1a locus. Cre recombinase 
knock-in mice Lyz2cre/cre mice (B6.129P2-Lyz2tm1(cre)Ifo) (Clausen et  al., 
1999) were obtained from the Jackson Laboratories at backcross gen-
eration N6 and were further backcrossed to N10 with C57BL6/J mice 
before intercrossing with Sb1aF/F mice to generate the desired geno-
types. Cre recombinase knock-in mice Cebpa+/cre mice (Cebpatm1(cre)Touw) 
were described previously (Wölfler et al., 2010).
Generation of human SERPINB1 transgenic mice
A 3.8 kb fragment upstream of the S100A8 start codon was amplified 
by PCR from a human BAC clone obtained from imaGenes (I.M.A.G.E. 
clone number RPCIB753O1168Q) and directionally cloned using 
NheI and SalI restriction digest upstream of human SERPINB1 cDNA 
flanked downstream by the SV40 small T intron and poly-adenyla-
tion signal. The final DNA construct was verified by sequencing and 
the plasmid backbone was excised by restriction digest with ClaI 
and NotI. The transgene band was separated by agarose electropho-
resis and gel purified. The transgene was microinjected in C57BL/6J 
oocytes at the Cryoconservation and Transgenic unit of the Theodor 
Kocher Institute, University of Bern. Four male and four female mice 
out of 21 total mice born were positive for the transgene by PCR. 
Three of the four transgene positive founder males transmitted the 
transgene to their progeny and were then crossed with Sb1a-/- mice. 
The transgene was always maintained as hemizygous. The progeny of 
each founder were handled as independent transgenic lines named 
Tgx (full nomenclature B6J-Tg(S100A8-SERPINB1)xCben), where ‘x’ 
represents the founder number.
Flow cytometry and cell sorting
Leukocyte counts and hematopoietic lineage differential analysis of 
BM was performed in mice aged 6–8-weeks old. BM cells were har-
vested from femurs by flushing with PBS supplemented with 1% FCS, 
red blood cells were lyzed with ammonium chloride for 10 min, fur-
ther washed in PBS and counted in a Neubauer chamber. Isolated BM 
cells were stained with fluorescently labeled antibodies (Biolegend 
and BD Biosciences) and analyzed on a FACScalibur flow cytometer 
(BD Biosciences) as described previously. Briefly, leukocyte subsets 
percentages were determined within CD45+ cells as PMNs (CD11b+Ly-
6G+), monocytes (CD115+), myelocytes (CD11b+, CD115neg, Ly6Gneg, 
SSChigh) and B cells (CD19+ or CD45RB220+). Blood was collected by 
retro-orbital venous puncture using heparinized microcapillary 
tubes and leukocyte subsets analyzed by flow cytometry as above. 
Total leukocyte, erythrocyte and platelet counts as well as hemo-
globin and hematocrit measurements of whole blood were performed 
using a Scil Vet ABC hematology analyzer (Horiba Medical, Montpel-
lier, France). Flow cytometry data was analyzed using FlowJo (FlowJo 
LLC). Flow sorting of PMNs, B cells and myelocytes was performed 
on single-cell suspensions of BM leukocytes stained with antibodies 
mentioned above using a FACS Aria II sorter (BD Biosciences) at the 
flow cytometry core facility of the Department of Clinical Research of 
the University of Bern.
Western blotting
Sorted cells were washed and lysed (107/ml) in RIPA buffer with 
protease inhibitor cocktail (Roche). Lysates were resolved by SDS-
PAGE under reducing conditions and immunoblotted using rabbit 
antiserum to human SERPINB1 provided by ERO (Rees et al., 1999). 
Blots were stripped and restained with anti-β-actin antibody (Cell 
 Signaling Technology).
Cell death induced by granule permeabilization
BM cells were cultured in DMEM (4 mm L-Glut, 25 mm D-Glucose, 
1 mm sodium pyruvate) (Life Technologies) containing 1% FCS and 
1% penicillin/streptomycin at 1.0 × 106 cells/ml in the presence or 
absence of the pan-caspase inhibitor Q-VD-OPh (SM Biochemicals 
LLC) or LLME (G-2550; Bachem). Cells were harvested and viability 
was assessed using annexin V–fluorescein isothiocyanate (FITC) and 
7-aminoactinomycin D (7AAD) and measured at the FACScalibur flow 
cytometer.
Statistical analysis
Leukocyte subset analysis was performed using Mann-Whitney 
U-test or Student’s t-test with GraphPad Prism Mac 4.0c software 
(GraphPad, San Diego, CA, USA). A p Value < 0.05 was considered sta-
tistically significant.
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